Rhelion Life Sciences Corp.
TRUFF
$0.02
$0.008.42%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.34% | 8.69% | -45.40% | -17.45% | -37.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.34% | 8.69% | -45.40% | -17.45% | -37.46% |
| Cost of Revenue | -18.47% | 20.82% | -48.19% | -9.58% | -35.60% |
| Gross Profit | 47.10% | -13.36% | -41.29% | -29.20% | -40.29% |
| SG&A Expenses | 16.36% | 10.81% | -8.82% | -23.51% | -41.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.02% | 14.70% | -17.50% | -19.46% | -40.38% |
| Operating Income | -7.58% | -21.81% | -34.57% | 21.64% | 42.56% |
| Income Before Tax | -114.95% | -57.22% | -102.56% | 15.29% | 55.88% |
| Income Tax Expenses | -193.22% | -38.51% | -255.29% | -371.43% | -14,275.00% |
| Earnings from Continuing Operations | -110.84% | -57.65% | -99.56% | 17.46% | 58.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 311.88% | -29.91% | -5.62% | -36.87% | 786.36% |
| Net Income | -86.68% | -62.41% | -104.07% | 17.03% | 62.39% |
| EBIT | -7.58% | -21.81% | -34.57% | 21.64% | 42.56% |
| EBITDA | -133.97% | -39.28% | -62.79% | 17.44% | 38.64% |
| EPS Basic | -79.17% | -60.00% | -110.00% | 21.74% | 63.08% |
| Normalized Basic EPS | 100.00% | -33.33% | -66.67% | 26.67% | 63.16% |
| EPS Diluted | -412.50% | -60.00% | -110.00% | 21.74% | 63.08% |
| Normalized Diluted EPS | 100.00% | -33.33% | -66.67% | 26.67% | 63.16% |
| Average Basic Shares Outstanding | 4.64% | 4.15% | 3.12% | 3.51% | 1.88% |
| Average Diluted Shares Outstanding | 4.64% | 4.15% | 3.12% | 3.51% | 1.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |